Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Vaccination Trial in Metastatic Uveal Melanoma Using IKKb-matured Dendritic Cells
NCT04335890Phase 1Completed
- Sponsor
- Hasumi International Research Foundation
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dendritic cell-cytokine-induced killer cells + Kanglaite + bevacizumab in Uveal melanoma (UM), sponsored by Hasumi International Research Foundation. Primary endpoints: Safety of DCIKKb at 1 year, Tolerability of DCIKKb at 1 year and 2 more. Started Sep 2020; status: completed.
02
Drugs
dendritic cell-cytokine-induced killer cells + Kanglaite + bevacizumab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT04335890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335890.